Small caps round-up: Orchid, Iofina, Phytopharm
Cash is extremely tight at the Bulgaria focused property company Orchid Developments Group, especially after a recent planned sale asset failed to go ahead for reasons beyond the control of Orchid. The firm has warned that it 'cannot be certain that it can continue to operate with the full support of its creditors', meaning that its cash position is now more uncertain than previously stated. Consequently, the group is now considering the best way to address its immediate working capital needs.
Cash is extremely tight at the Bulgaria focused property company Orchid Developments Group, especially after a recent planned sale asset failed to go ahead for reasons beyond the control of Orchid. The firm has warned that it 'cannot be certain that it can continue to operate with the full support of its creditors', meaning that its cash position is now more uncertain than previously stated. Consequently, the group is now considering the best way to address its immediate working capital needs.
Iodine maker Iofina has successfully commissioned its IO#1 plant, marking a significant milestone for the firm. The tie-in to the electricity grid was completed on schedule in early August. The firm has now commenced processing iodine-rich brine from the producer's salt water disposal site and the company is now on track to become a major iodine producer.
Phytopharm, a developer of pharmaceuticals, is expecting the headline results from its phase two clinical study on its Cogane product in patients with Parkinson's disease in February 2013, saying it has already demonstrated efficacy in the "gold standard" pre-clinical model of ALS, the most common form of motor neurone disease. The firm is growing confident that the drug offers a potential treatment for the condition. The company is now preparing for a phase one study to evaluate Cogane solid dose formulations for up to 28 days.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
NR
-
FTSE 100 hits record highs – why is it rising and will we see more gains?
Advice UK equities have been described as unloved for a long time but as the FTSE 100 hits new highs, we explain if now is the time to buy British.
By Marc Shoffman Published
-
How to invest in copper
It may be time to invest in copper as the red metal appears poised for a big jump. Dominic Frisby looks at what should investors should buy
By Dominic Frisby Published